Novel by Upper Airway Respiratory Muscle Training to Treat OSA in Chronic SCI
NCT ID: NCT03664765
Last Updated: 2024-03-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
29 participants
INTERVENTIONAL
2019-01-01
2022-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Inspiratory Muscle Training Improves the Severity of Obstructive Sleep Apnea and Sleep Quality?
NCT02963844
Airway Muscle Training for Obstructive Sleep Apnea
NCT02259660
Respiratory Muscle Training in Acquired Brain Injury Patients.
NCT06070831
Effect of Inspiratory Muscle Training in Obstructive Sleep Apnea Syndrome.
NCT06117579
Respiratory Muscle Training in Adults With Spinal Cord Injury
NCT05904600
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this application is to identify new therapeutic interventions for OSA treatment in Veterans with SCI/D. This application proposes for a pilot study to randomizing 30 Veterans with SCI/D and OSA to receive 3 months of daily (30 minutes) treatment with a validated set of oropharyngeal and RMT (intervention arm) versus sham therapy (control arm). There will be three specific aims to address the following hypotheses:
Specific Aim (1): To test recruitment rate and feasibility of a pilot intervention that includes combined oropharyngeal and RMT versus sham treatment in individuals with SCI/D.
Specific Aim (2): To test the acceptability and usability of combined oropharyngeal and RMT in individuals with SCI/D.
Specific Aim (3): To determine the effect size estimates for clinical endpoints and their associated variability at the end of treatment to calculate an appropriate sample size for an adequately powered clinical trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention exercise arm
daily oropharyngeal and respiratory muscle exercises
UA and RMT
daily oropharyngeal and respiratory muscle exercises
Control arm
Daily sham exercises
Sham exercise
Daily sham exercises
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UA and RMT
daily oropharyngeal and respiratory muscle exercises
Sham exercise
Daily sham exercises
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Spinal Injury Association (ASIA) classification A-D who have evidence of OSA
* excluding those with no evidence of a neurologic deficit based on ASIA classification
* Specifically, the study will target those with SCI/D and OSA who would like alternative treatment options or to have a lower PAP pressure, if they refused, or did not tolerate PAP treatment
Exclusion Criteria
* except PAP therapy which is considered usual treatment for SDB)
* Severe congestive heart failure with ejection fraction \<35%
* Recent health event that may affect sleep
* stroke
* acute myocardial infarction
* recent surgery
* hospitalization
* Alcohol or substance abuse (\<90 days sobriety)
* Self-described as too ill to engage in study procedures
* Unable to provide self-consent for participation
* Central sleep apnea (CSA) defined as central apnea/hypopnea index \>50% of the AHI
18 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdulghani Sankari, MD PhD
Role: PRINCIPAL_INVESTIGATOR
John D. Dingell VA Medical Center, Detroit, MI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
John D. Dingell VA Medical Center, Detroit, MI
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2885-P
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.